Belite Bio, Inc (BLTE)

Belite Bio Statistics

Total Valuation

Belite Bio has a market cap or net worth of $5.67 billion. The enterprise value is $5.18 billion.

Market Cap	5.67B
Enterprise Value	5.18B

Important Dates

The last earnings date was Wednesday, May 20, 2026, before market open.

Earnings Date	May 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Belite Bio has 39.34 million shares outstanding. The number of shares has increased by 13.95% in one year.

Current Share Class	n/a
Shares Outstanding	39.34M
Shares Change (YoY)	+13.95%
Shares Change (QoQ)	+10.08%
Owned by Insiders (%)	1.79%
Owned by Institutions (%)	15.85%
Float	18.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	7.13
P/TBV Ratio	7.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 33.71

Current Ratio	33.71
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-50,687.50

Financial Efficiency

Return on equity (ROE) is -18.93% and return on invested capital (ROIC) is -13.28%.

Return on Equity (ROE)	-18.93%
Return on Assets (ROA)	-12.99%
Return on Invested Capital (ROIC)	-13.28%
Return on Capital Employed (ROCE)	-12.74%
Weighted Average Cost of Capital (WACC)	-2.31%
Revenue Per Employee	n/a
Profits Per Employee	-$2.20M
Employee Count	41
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +134.02% in the last 52 weeks. The beta is -1.19, so Belite Bio's price volatility has been lower than the market average.

Beta (5Y)	-1.19
52-Week Price Change	+134.02%
50-Day Moving Average	157.13
200-Day Moving Average	133.04
Relative Strength Index (RSI)	42.58
Average Volume (20 Days)	178,145

Short Selling Information

The latest short interest is 1.23 million, so 5.96% of the outstanding shares have been sold short.

Short Interest	1.23M
Short Previous Month	1.11M
Short % of Shares Out	5.96%
Short % of Float	n/a
Short Ratio (days to cover)	8.83

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-101.38M
Pretax Income	-90.27M
Net Income	-90.27M
EBITDA	-101.19M
EBIT	-101.38M
Earnings Per Share (EPS)	-$2.54

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	795.79M
Book Value Per Share	20.23
Working Capital	506.38M

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	188,000
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Belite Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.95%
Shareholder Yield	-13.95%
Earnings Yield	-1.59%
FCF Yield	n/a

Analyst Forecast

The average price target for Belite Bio is $210.50, which is 46.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$210.50
Price Target Difference	46.00%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1